Published on 6/11/2019 11:39:04 AM | Source: Motilal Oswal Services Ltd

Buy Coromandel International Ltd For The Target Rs.600 - Motilal Oswal

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel 

Download Telegram App before Joining the Channel

Higher manufacturing volumes support margins

New phosphoric acid plant to aid in reducing RM cost

* Beat on all fronts: 2QFY20 revenue declined 3% YoY to INR48.6b (v/s est. INR44.4b). EBITDA margin expanded 140bp YoY to 14.7% (v/s est. 14%) and EBITDA grew 7% YoY to INR7.1b (v/s est. INR6.2b). PBT was up 6% YoY to INR6,145m. Adj. PAT grew 33% YoY to INR5b (v/s est. INR4b) on account of lower tax rate. In 1HFY20, revenue declined 7% YoY while EBITDA/PAT grew 3%/21% YoY

* Fertilizer segment drives performance: Nutrient and other allied segment revenue declined 2% YoY (to INR43.9b) with 160bp EBIT margin expansion (to 14.3%), due to higher manufacturing volumes. CRIN has contracted phosphoric acid at USD625/MT for 3QFY20 (v/s USD655/MT in 2QFY20). According to our calculations, in 2QFY20, EBITDA/MT for manufacturing fertilizer stood at INR4,067/MT (+1% YoY; +14% QoQ). Plant protection revenue declined 11% YoY (to INR5.1b) with EBIT margin contraction of 210bp (to 16.3%) on account of delay in stabilization of Sarigam plant (which resumed operations in mid-Jul’19) and softness in mancozeb prices. 

* Key concall takeaways: (i) MRP of phosphatic fertilizers declined 10% owing to decrease in RM cost, (ii) Company expects revenue to remain flat in crop protection segment for FY20, and (iii) CRIN has guided EBITDA/MT at INR3,500/MT for manufacturing fertilizer in FY20. 

* Valuation and view: Factoring in the strong beat on all fronts (revenue, EBITDA and PAT) during 2QFY20, we increase our PAT estimates by 15%/14% for FY20/21. Additionally, the rising backward integration (post commencement of new phos acid plant) and the decline in phos acid prices should drive margin expansion for CRIN. We expect revenue/EBITDA/PAT CAGR of 4%/12%/22% over FY19-21 and value the stock at 16x FY21E EPS (it has traded at an average P/E of 17x over the last five years). Our TP of INR600 implies 28% upside. Maintain Buy


To Read Complete Report & Disclaimer Click Here


For More Motilal Oswal Securities Ltd Disclaimer SEBI Registration number is INH000000412


Above views are of the author and not of the website kindly read disclaimer